Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

A, Woolloongabba N Clinical Trials

A listing of A, Woolloongabba N clinical trials actively recruiting patients volunteers.


Found (104) clinical trials

IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)

The multimodal approach of combining peri-interventional administration of an immune checkpoint inhibitor and local ablation via RFA / MWA harbors the potential to satisfy the unmet need for an improvement in the outcomes of HCC patients treated with RFA / MWA. Furthermore, early clinical data indicates that the combination of ...


N-Acetyl-L-Leucine for GM2 Gangliosdisosis (Tay-Sachs and Sandhoff Disease)

The primary purpose of the study is to evaluate the safety and efficacy of N-Acetyl-L-Leucine (IB1001) in the treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease), investigating the efficacy in terms of improving symptoms, functioning, and quality of life against the defined endpoints in patients with GM2 Gangliosidosis. Patients will ...


Compare the Efficacy and Safety of Beta-Glucan as Add-On to Statin in Subjects With Hyperlipidemia.

Male and female subjects 18 years of age with an elevated LDL-C > 3.37 mmol/L (130 mg/dL) treated with a stable dose of statin for at least 6 weeks (atorvastatin (10-20mg daily) or equivalent dose of another statin), including subject with previous cardiovascular (CV) events, with partial statin intolerance defined ...


Treg/Tcon Immunotherapy Combined With High Dose Irradiation in HSCT

Improving cGvHD/disease free survival in patients with high-risk acute leukemias or other hematologic malignancy where HSCT is indicated whit the use of a regulatory T cell based protocol. Hyper-fractionated Total Body Irradiation or Total Marrow and Lymphoid Irradiation based conditioning will be followed by the infusion of T regulatory and ...


Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former Smokers

The purpose of this study is to find out if an investigational combination drug called Lovaza (made with fish oils)+Curcumin C3 Complex (made from a root called curcumin) can help reduce the size of lung nodules. Researchers also want to find out if the combination of Lovaza+Curcumin C3 Complex is ...


Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet

This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while giving a therapeutic dose to ...


Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The FDA (the U.S. Food and Drug Administration) has ...


Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)

Squamous-cell lung cancer (SQCLC) is a distinct histologic subtype of non-small cell lung cancer (NSCLC) that is challenging to treat because of specific clinicopathologic characteristics (older age, advanced disease at diagnosis, central location of tumors) and the absence of molecular alterations, which can be successfully treated with targeted therapy. A ...


Evaluation of Ocoxin -Viusid in Advanced Stomach Cancer and Gastric Esophagogastric Junction

To evaluate the effect of Ocoxin-Viusid on the quality of life of patients To evaluate the toxicity of Ocoxin-Viusid in combination with chemotherapy (QT). To assess the influence of Ocoxin-Viusid on tolerance to treatment with chemotherapy. Identify the changes that occur in the nutritional status of patients receiving the supplement.


Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

The trial will enroll up to 20 participants. Following enrollment, participants will be initially treated with olaparib 150mg by mouth twice daily for one month. After one month of therapy, the dose of olaparib will be increased to 300mg by mouth twice daily provided there are no grade 3 or ...